CDT任命联合创始人James Bligh为CEO并重申Sarborg投资方向

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 01, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“
CDT
” or the “
Company
”) today announced the appointment of James Bligh, co-founder of Conduit Pharmaceuticals Limited (now CDT), as Chief Executive Officer. Mr. Bligh brings extensive public-markets, corporate finance and transaction experience to the role and will lead the Company as it enters its next phase of growth and value creation. Dr. Andrew Regan has been appointed as CEO of Sarborg Limited.
Mr. Bligh co-founded Conduit Pharmaceuticals Limited in 2019 and has played an important role in the development and evolution of the business. Prior to Conduit, he spent more than a decade leading and advising on reverse takeovers, stock-market listings, initial public offerings, secondary fundraisings and M&A transactions. He has also held financial officer positions and served on a number of corporate boards and audit-related committees.
His appointment follows a period of significant development for CDT, including strengthening the Company’s balance sheet, reducing its operating cost base and completing strategic investments intended to create long-term shareholder value. These include CDT’s acquisition of a significant stake in Sarborg, a quantum signature intelligence business, as well as the re-structuring the Company’s loan notes and funding facilities.
“Having co-founded Conduit in 2019, I am delighted to take on the role of CEO at what I believe is an important point in the Company’s evolution. We have made significant progress establishing a portfolio of assets and investments that we believe have the potential to generate meaningful value for shareholders,” said James Bligh. “We will continue pursuing CDT’s strategy of identifying and targeting high-potential, science-driven and data-backed opportunities.”
CDT holds a 22% strategic investment in Sarborg and intends to continue working closely with the company as it develops its signature intelligence platform, expands its proprietary intellectual property portfolio and advances SarborgQ.
“I am excited to be CEO of Sarborg, following the significant growth to date. With the launch of SarborgQ and the application of quantum computing to signature intelligence, the market is moving so fast that it warrants my full-time attention. I feel confident that CDT's stake in Sarborg will prove to be an excellent investment and gain recognition in the value and share price of CDT," said Dr. Andrew Regan
About CDT Equity Inc.
CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT's future results of operations and financial position, CDT's business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT's control, you should not rely on these forward-looking statements as predictions of future events.
Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.
Investors
CDT Equity Inc.
Info@cdtequity.com